Sistema de Información Esencial en Terapéutica y Salud

@SIETES7

Última actualización: 7/7/2020
SIETES contiene 93061 citas

 
 
 1 a 20 de 15072 siguiente >>
Presentar resultados
Seleccionar todas
1. Cita con resumen
Arshad S, Kilgore P, Chaudhry ZS, Jacobsen G, Wang DD, Huitsing K, Brar I, Alangaden GJ, Ramesh MS, McKinnon JE, O'Neill W, Zervos M, Henry Ford COVID-19 Task Force. Treatment with hydroxychloroquine, azithromycin, and combination in patients hospitalized with COVID-19. International Journal of Infectious Diseases 2020:1 de julio. [Ref.ID 103682]
2.Enlace a cita originalTiene citas relacionadas Cita con resumen
Moynihan R, MacDonald H, Bero L, Godlee F. Commercial influence and covid-19. BMJ 2020;369:24 de junio. [Ref.ID 103680]
3. Cita con resumen
4. Cita con resumen
Deftereos SG, Giannopoulos G, Vrachatis DA, Siasos GD, Giotaki SG, Gargalianos P, Metallidis S, Sianos G, Baltagiannis S, Panagopoulos P, et al.. Effect of colchicine vs standard care on cardiac and inflammatory biomarkers and clinical outcomes in patients hospitalized with coronavirus disease 2019. The GRECCO-19 randomized clinical trial. JAMA Network Open 2020;3:24 de junio. [Ref.ID 103674]
5. Cita con resumen
Addis A, Ganazzani A, Trotta MP, Magrini N, for the Italian Medicines Agency Scientific Committee and COVID-19 Crisis Unit. Promoting better clinical trials and drug information as public health interventions for the COVID-19 emergency in Italy. Ann Intern Med 2020:16 de junio. [Ref.ID 103673]
6. Cita con resumen
Taylor P. Gilead will test inhaled remdesivir in earlier-stage COVID-19. PMLiVE 2020:23 de junio. [Ref.ID 103672]
8.Enlace a cita original Cita con resumen
Samper E. Así afectan las prisas a la ciencia que rodea al coronavirus . eldiario.es 2020:23 de junio. [Ref.ID 103667]
11. Cita con resumen
12. Cita con resumen
Rome BN, Avorn J. Drug evaluation during the covid-19 pandemic. N Engl J Med 2020;382:11 de junio. [Ref.ID 103661]
13. Cita con resumen
Taylor P. COVID-19 round-up: medicines on trial. PMLiVE 2020:9 de junio. [Ref.ID 103659]
14. Cita con resumen
Tang W, Cao Z, Han M, Wang Z, Chen J, Sun W, Wu Y, Xiao W, Liu S, Chen E, Chen W, Wang X, Yang J, Lin J, Zhao Q, Yan Y, Xie Z, Li D, Yang Y, Liu L, Qu J, Ning G, Shi G, Xie Q. Hydroxychloroquine in patients with mainly mild to moderate coronavirus disease 2019: open label, randomised controlled trial. BMJ 2020;369:14 de mayo. [Ref.ID 103652]
15. Cita con resumen
Mahévas M, Tran V-T, Roumier M, Chabrol A, Paule R, Guillaud C, Fois E, Lepeule R, Szwebel T-A, Lescure F-X, Schlemmer F, Matignon M, Khellaf M, Crickx E, Terrier B, Morbieu C, Legendre P, Dang J, Schoindre Y, Pawlotsky J-M, Michel M, Perrodeau E, et al.. Clinical efficacy of hydroxychloroquine in patients with covid-19 pneumonia who require oxygen: observational comparative study using routine care data. BMJ 2020;369:14 de mayo. [Ref.ID 103651]
16. Cita con resumen
18. Cita con resumen
Wise J. Covid-19 and thrombosis: what do we know about the risks and treatment?. BMJ 2020;369:21 de mayo. [Ref.ID 103635]
19.Tiene citas relacionadas Cita con resumen
Mehra MR, Desai SS, Ruschitzka F, Patel AN. Hydroxychloroquine or chloroquine with or without a macrolide for treatment of COVID-19: a multinational registry analysis. Lancet 2020:22 de mayo. [Ref.ID 103632]
20.Tiene citas relacionadas Cita con resumen
Beigel JH, Tomashek KM, Dodd LE, Mehta AK, Zingman BS, Kalil AC, Hohmann E, Chu HY, Luetkemeyer A, Kline S, Lopez de Castilla D, Finberg RW, et al. for the ACTT-1 Study Group Members. Remdesivir for the treatment of covid-19 — Preliminary report. N Engl J Med 2020:22 de mayo. [Ref.ID 103631]
Seleccionar todas
 
 1 a 20 de 15072 siguiente >>